Concepedia

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón, CM Wheeler, S-N Chow, Dan Apter, Henry C Kitchener, Xavier Castellsagué, JC Teixeira, S. Rachel Skinner,

The Lancet · 2009 · 1.7K citations · 23 references

DOI

Concepts

References

23

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

, , +16

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

, , +16

Prevalence of HPV Infection Among Females in the United States

Eileen F. Dunne, Elizabeth R. Unger, Maya Sternberg et al. · JAMA · 2007 · 1.6K citations · Full text

, , +15

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

, , +17

The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice

Michelle J. Khan, Philip E. Castle, Attila T. Lörincz et al. · JNCI Journal of the National Cancer Institute · 2005 · 1.1K citations · Full text

, , +16